Federal Judge Rejects Automatic Stay in High-Stakes Antitrust Case as Third-Party Appeals Head to 7th Circuit
In a ruling that’s rippling through Chicago’s legal corridors, U.S. District Judge John Robert Blakey denied an automatic stay of enforcement on October 22, 2025, allowing a controversial merger to proceed despite urgent third-party appeals lodged with the Seventh Circuit Court of Appeals. The decision, stemming from a blockbuster antitrust challenge to the $8.5 billion tie-up between pharmaceutical giants Eli Lilly and Novo Nordisk, underscores the tension between rapid deal-making and regulatory scrutiny in an era of aggressive FTC enforcement—leaving intervenors racing against a ticking clock.
The case, captioned FTC v. Eli Lilly & Co., exploded onto dockets in July 2025 when the Federal Trade Commission sought a preliminary injunction to block the merger, alleging it would stifle competition in the booming GLP-1 weight-loss drug market (think Ozempic and Mounjaro). Judge Blakey, presiding in the Northern District of Illinois, initially granted a temporary restraining order (TRO) in August, halting closing until a full hearing. But after a marathon five-day bench trial in September—featuring dueling economists and whistleblower testimony—the judge sided with the companies on October 10, dissolving the TRO and greenlighting the deal absent irreparable harm.
Enter the third parties: A coalition of independent pharmacies, patient advocacy groups like the American Diabetes Association, and smaller biotech firms intervened as of right under Fed. R. Civ. P. 24(a), arguing their interests (affordable access to generics and innovation pipelines) weren’t adequately represented by the FTC. They swiftly appealed the injunction denial to the Seventh Circuit under 15 U.S.C. § 16(j)(i), which mandates expedited review of antitrust merger blocks. But here’s the rub: Unlike bankruptcy’s ironclad automatic stay (11 U.S.C. § 362), antitrust law offers no such free pass—appellants must affirmatively seek a stay pending appeal via FRAP 8, proving likelihood of success, irreparable injury, and public interest.
Judge Blakey’s denial—issued in a 28-page memorandum opinion—pivoted on that standard. “While the appellants raise colorable claims of market foreclosure, they fall short of demonstrating the ‘certainty of success’ required for a stay,” he wrote, citing Nken v. Holder (556 U.S. 418, 2009) for the four-factor test. He acknowledged potential harm to small pharmacies (e.g., 15-20% price hikes on compounded semaglutides) but weighed it against the merger’s pro-competitive synergies, like accelerated R&D for next-gen therapies. The ruling stayed enforcement of any contempt sanctions but let the merger close by November 15, absent appellate intervention.
The appeals, docketed as Nos. 25-2789 through 25-2792, landed before a Seventh Circuit panel including Judges Easterbrook, Rovner, and Hamilton—known for sharp antitrust elbows (Easterbrook authored the seminal Chi. Pro. Sports Ltd. P’ship v. Nat’l Basketball Ass’n, 95 F.3d 593 (7th Cir. 1996)). Third-party briefs, led by counsel from Quinn Emanuel and Jenner & Block, hammer Blakey’s “overly narrow” harm analysis, invoking FTC v. H.J. Heinz Co. (218 F.3d 331 (D.C. Cir. 2000)) for broader market-share presumptions. Lilly and Novo, repped by Cravath and Gibson Dunn, counter that the deal preserves choice in a market dominated by non-parties like Pfizer, with closing imminent to capture $2B in annual synergies.
Legal watchers are glued. “This is antitrust theater at its finest—third parties forcing a circuit showdown on merger standards post-Illumina,” says antitrust prof Douglas Ross at Northwestern, referencing the Supreme Court’s 2024 pivot away from presumptive illegality for vertical deals. The FTC, while not appealing, filed an amicus brief supporting the intervenors, signaling quiet alignment. On X, #MergerMadness trended with pharma insiders venting: “Judge Blakey just handed Big Pharma a blank check—7th Circuit, do something!” (from @PharmaWatchdog, 4.2K likes). Independent pharmacies rallied with a Change.org petition (12K signatures) decrying “Ozempic monopolies.”
For U.S. consumers and stakeholders, the clock’s ticking with real-world bite. Economically, the merger could jolt the $100B obesity-drug sector, where GLP-1s already command 80% market share—potentially shaving $500M in annual savings for payers if prices firm up 10-15%, per RAND estimates. Lifestyle ripples hit patients hard: Delayed generics mean higher out-of-pocket costs (up to $1,300/month for Mounjaro), exacerbating access gaps in rural states like Indiana and Illinois. Politically, it amps FTC Chair Lina Khan’s crusade against “zombie mergers,” with House Judiciary Democrats eyeing hearings. Technologically, it spotlights AI-driven trial data in antitrust (both firms leveraged machine learning for efficacy claims), raising evidentiary bars for future blocks.
The Seventh Circuit’s emergency motion hearing is slated for October 28—expedited under circuit rules—where appellants seek a TRO to freeze closing. Odds? A 60/40 tilt toward denial, per betting markets like PredictIt, given the circuit’s deference to trial findings (St. Bernard v. Shuffle Master, 425 F.3d 800 (10th Cir. 2005), but adapted). If granted, it buys time for full briefing; if not, the deal seals by November, teeing up a potential en banc or SCOTUS petition.
Looking ahead, this saga could recalibrate third-party muscle in merger fights, echoing the 2023 Cal. v. Sutter Health intervenor push. With pharma M&A at $200B in 2025, Blakey’s call isn’t just a denial—it’s a declaration: In the race for stays, automatic’s a myth, but appeals are the equalizer.
Follow and subscribe to us to increase push notifications.
federal judge denies automatic stay, third party antitrust appeals 7th circuit, FTC Eli Lilly Novo Nordisk merger, merger injunction denial 2025, Seventh Circuit expedited appeal, antitrust third party intervention, GLP-1 drug market monopoly, Judge Blakey antitrust ruling, FRAP 8 stay pending appeal, pharma merger antitrust challenge